Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson's Disease and Movement Disorders® 2025

H. Lundbeck A/S (Lundbeck) today announced that pipeline developments regarding amlenetug, a novel investigational molecule for the potential treatment of Multiple System Atrophy (MSA), will be ...
BioWorld

University of California divulges new α-synuclein, amyloid-β protein and MAPT propagation inhibitors

The University of California has synthesized α-synuclein (SNCA) and/or amyloid-β protein and/or microtubule-associated protein tau (PHF-tau; MAPT) propagation inhibitors reported to be useful for ...

Alterity Therapeutics (ATHE) Presents Positive Phase 2 Data for ATH434

Alterity Therapeutics Limited (NASDAQ:ATHE) is one of the best performing ASX stocks in 2025. On September 15, the company ...

StockTake: Alterity’s ATH434 shows US$2.4b potential for treating MSA

Host Tylah Tully looks at Alterity Therapeutics (ASX:ATH) and the highlighted multi billion dollar potential of its lead ...
Center for International Maritime SecurityOpinion

Fix the Navy’s Flawed System of Warfighting Development

A pointed example of the U.S. Navy’s atrophy in warfighting development can be seen in its combat training program and weak ...